|
21 Companies |
|
32 Products |
|
32 Products |
|
37 Mechanisms of Action |
|
0 Trials |
|
64 News |
|
| «12 |
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 24
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 24 Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: Interleukin-2 in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 11, 2012
P1, N=24, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclosporine / Generic mfg.
Clinical: Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low study accrual
- cyclophosphamide / Generic mfg.
Trial completion: Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) - Oct 23, 2012
P2, N=72, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Terminated; low study accrual Active, not recruiting --> Completed
- Zamyl (lintuzumab) / Pfizer
Trial termination: Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 10, 2012
P2, N=7, Terminated, Sponsor: Alison Walker
Active, not recruiting --> Completed Not yet recruiting --> Terminated; Drug no longer being supplied by sponsor
- Zamyl (lintuzumab) / Pfizer
Enrollment change: Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 10, 2012
P2, N=7, Terminated, Sponsor: Alison Walker
Not yet recruiting --> Terminated; Drug no longer being supplied by sponsor N=35 --> 7
- Enrollment change, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=35 --> 7 N=120 --> 148
- Trial completion, Metastases: Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=148, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=120 --> 148 Terminated --> Completed
- Remicade (infliximab) / J&J
Enrollment change: Infliximab in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 12, 2012
P2, N=46, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Terminated --> Completed N=80 --> 46
- Remicade (infliximab) / J&J
Trial completion: Infliximab in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 12, 2012
P2, N=46, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=80 --> 46 Active, not recruiting --> Completed
- arsenic trioxide / Generic mfg.
Trial termination: Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 11, 2012
P2, N=5, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Active, not recruiting --> Terminated; sponsor discontinues support
- | cyclosporine / Generic mfg.
Trial completion: SAKK 33/99: Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 9, 2012
P3, N=86, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Terminated; sponsor discontinues support Active, not recruiting --> Completed
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial termination: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=3, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Suspended --> Terminated; Slow accrual
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=3, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Suspended --> Terminated; Slow accrual N=36 --> 3
- cyclosporine / Generic mfg.
Trial completion: S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 12, 2012
P2, N=130, Completed, Sponsor: Southwest Oncology Group
N=36 --> 3 Active, not recruiting --> Completed
- Trial completion: Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 4, 2011
P2, N=34, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment closed: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 23, 2011
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting